MAM
Vikram Hemdev joins as COO of Laqshya Hyderabad Airport Media
NEW DELHI: Laqshya Media has got on board Vikram Hemdev as COO – Laqshya Hyderabad Airport Media Pvt Ltd (LHAMPL), the joint venture between Laqshya Media Limited and GMR group.
Prior to joining Laqshya Media, Hemdev’s last assignment was with Times OOH as the business head – traditional out of home & trading. He also successfully handled the Delhi Airport & Mumbai Airport advertising business during critical junctures.
He comes with 18 years of rich experience across the media & advertising landscape, sales & marketing, business operations and P&L management. Hemdev has been associated with the Bennett & Coleman Group for more than a decade handling multiple responsibilities across radio, activations, airport advertising & traditional OOH. In the past he has worked with organisations such as Mercedes-Benz, McCann, Ogilvy, Indian Express & Mphasis.
Hemdev is coming in place of Shashi Sinha who helmed this business for over 10 years. Sinha has had a 12-year-long and successful stint at Laqshya Group with all their business divisions – media assets, OMI and Hyderabad Airport.
About his new role, Hemdev says, “I am very happy to be a part of Laqshya, especially at a time when the OOH industry is going through a reset. The next few months are the most challenging and all our collective experiences are going to get thoroughly tested. I am looking forward to add value, rebuild the airport advertising business, move it in a positive direction and hopefully set new benchmarks.”
Laqshya Media Group CEO Atul Shrivastava said, “Laqshya Media Group is very happy to welcome Vikram Hemdev as the COO of LHAMPL. Post lockdown the demand for travel is seeing a steady increase and air-travel is seen as one of the safest modes of transport. The dwell time at airports has increased significantly and consumers are more alert than ever. A lot of brands have already positioned themselves at Hyderabad Airport keeping the new normal in mind & it is only poised to increase further, very soon!
At this juncture we are delighted to have on board Vikram’s expertise and fresh ideas. I am sure he will take LHAMPL to greater heights. We wish him every success.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
